Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures.

Jeffrey R. Dahlen, PhD, 3985 Sorrento Valley Boulevard, San Diego, CA 92121, USA, Tel.: +1 858 404 8247, Fax: +1 858 875 0602, E-mail: .
Thrombosis and Haemostasis (Impact Factor: 5.76). 12/2012; 109(2). DOI: 10.1160/TH12-08-0608
Source: PubMed

ABSTRACT Various diagnostic and prognostic performance measures have been used to describe the clinical usefulness of platelet function testing in the evaluation and management of patients taking P2Y 12 inhibitors, which reduce the risk for thrombosis due to their action on the platelet P2Y 12 receptor. Platelet function tests are used to confirm the presence of an antiplatelet effect of a P2Y 12 inhibitor, and confirmation that the pharmacodynamic effect is associated with a reduction in the rate of thrombosis. Despite this clear association, enthusiasm for the clinical usefulness of platelet function testing has been tempered based on observed sensitivity, specificity, and positive predictive value for the detection of future thrombotic events. However, evaluating the prognostic utility of a test based on diagnostic performance indicators is not appropriate because prognostic tests are not used to diagnose which patients will have events; instead, they are used to assist in risk stratification. Therefore, when evaluating the usefulness of platelet function testing, diagnostic performance measures such as sensitivity, specificity, and predictive values should focus on diagnostic performance in identifying a pharmacodynamic effect, and prognostic performance should be evaluated using prognostic performance measures such as hazard ratios and net reclassification improvement, which are comparable to other well-established risk factors for cardiovascular events.

1 Follower
  • Source
    Journal of Vascular and Interventional Radiology 03/2014; 25(3):S92-S93. DOI:10.1016/j.jvir.2013.12.261 · 2.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prognostic factors are associated with the risk of future health outcomes in individuals with a particular health condition. The prognostic ability of such factors is increasingly being assessed in both primary research and systematic reviews. Systematic review methodology in this area is continuing to evolve, reflected in variable approaches to key methodological aspects. The aim of this article was to (i) explore and compare the methodology of systematic reviews of prognostic factors undertaken for the same clinical question, (ii) to discuss implications for review findings, and (iii) to present recommendations on what might be considered to be 'good practice' approaches. The sample was comprised of eight systematic reviews addressing the same clinical question, namely whether 'aspirin resistance' (a potential prognostic factor) has prognostic utility relative to future vascular events in patients on aspirin therapy for secondary prevention. A detailed comparison of methods around study identification, study selection, quality assessment, approaches to analysis, and reporting of findings was undertaken and the implications discussed. These were summarised into key considerations that may be transferable to future systematic reviews of prognostic factors. Across systematic reviews addressing the same clinical question, there were considerable differences in the numbers of studies identified and overlap between included studies, which could only partially be explained by different study eligibility criteria. Incomplete reporting and differences in terminology within primary studies hampered study identification and selection process across reviews. Quality assessment was highly variable and only one systematic review considered a checklist for studies of prognostic questions. There was inconsistency between reviews in approaches towards analysis, synthesis, addressing heterogeneity and reporting of results. Different methodological approaches may ultimately affect the findings and interpretation of systematic reviews of prognostic research, with implications for clinical decision-making.Systematic review registration: This review of systematic reviews in one medical area has been used to generate a number of recommendations for those undertaking systematic reviews of prognostic research; these include a step-wise hierarchical approach to study selection and suggested approaches for analysis (e.g. maximisation of data for meta-analysis). This work adds to and extends the growing body of methodological evidence in this field.
    12/2014; 3(1):140. DOI:10.1186/2046-4053-3-140
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The role of platelet function testing in acute coronary syndrome patients undergoing percutaneous coronary intervention remains controversial despite the fact that high platelet reactivity is an independent predictor of stent thrombosis and emerging evidence suggests also a link between low platelet reactivity and bleeding. In this expert opinion paper, the Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association and the Working Group on Thrombosis of the European Society of Cardiology aim to provide an overview of current evidence in this area and recommendations for practicing clinicians.
    Thrombosis and Haemostasis 11/2014; 113(1). DOI:10.1160/TH14-05-0449 · 5.76 Impact Factor